FLT3 and acute myeloid leukemia: This small molecule with inhibitory activity has been shown to be effective with up-front AML targeting both AML with internal tandem duplication (FLT3-IDT) and those carrying mutations in the tyrosin kinase domain (FLT3-TKD).